

Structural Genomics from Inside Biopharma and the Future

J Michael Sauder¹

¹Lilly Biotechnology Center
michael.sauder@lilly.com

A retrospective of structural genomics from within the biotech and pharma industry will be presented along with a perspective on the future of structural sciences in the biopharma industry. My first exposure to structural genomics was at the 1998 Avalon, NJ meeting, which initiated my career in structural bioinformatics. From 2000-2008 I worked at Structural GenomiX, later SGX Pharmaceuticals, which became a protein production center during the first phase of the NIGMS-funded Protein Structure Initiative, and one of the large scale production centers during PSI-2. During this time, SGX was involved in internal drug discovery research, multiple commercial collaborations, and work with academic and non-profit organizations. In 2008 the company was acquired by Eli Lilly & Company and moved to a new site, all the while continuing its structural genomics efforts. I will provide some perspective on the first “PSI” decade, the following decade focused on using structural data to accelerate pharmaceutical discovery research, and the current decade of artificial intelligence.